Ubichem Group adds manufacturing site in Hungary

Published: 13-Jun-2012
Ingredients Pharmaceutical

To produce fine chemicals in large quantities and expand presence in non-pharma sector


Ubichem Group has acquired a 55,000m2 facility in Budapest, Hungary, enabling it to produce fine chemicals in multi-ton quantities.

The new plant also expands Ubichem Group’s presence in the non-pharma sector.

Ubichem Pharma Manufacturing will be producing starting materials, intermediates and other fine chemical products for pharma and non-pharma applications at the plant.

‘This new plant represents a milestone in Ubichem history,’ says chief executive József Répási. ‘From now on we are able to provide a comprehensive range of services from process r&d through pilot-scale cGMP API manufacture to high-volume manufacturing.’

He added: ‘We believe we have a competitive edge over intermediate manufacturers based in Asia by leveraging a highly skilled talent pool of chemists and by meeting high quality expectations and strict deadlines for our customers.’

  • Companies:
  • Ubichem
See more

You may also like

Ingredients

Ubichem - Informex 2009 Showcase

Read more
Ubichem provides manufacturing, sourcing and supply chain solutions to the pharmaceutical and related industries.

Trending Articles

  1. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  2. Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
  3. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  4. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  5. Abzena Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor our strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule. Our global locations include San Diego (CA, USA), Bristol (PA, USA), and Cambridge (UK).

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Ingredients

Ubichem - Informex 2009 Showcase

<p>Ubichem provides manufacturing, sourcing and supply chain solutions to the pharmaceutical and related industries.</p>
Manufacturing

New facilities significantly extend Ubichem capacity

<p>Ubichem, of Eastleigh in the UK, is investing in additional production capacity in its facilities in Budapest, Hungary. </p>
Ingredients

Ubichem approved for commercial cGMP API production

<p>Ubichem Research, in Eastleigh, UK and Budapest, Hungary, has completed its first regulatory audit and is now approved by OGYI (Hungarian National Institute for Pharmacy) for the commercial supply of cGMP Active Pharmaceutical Ingredients (APIs). </p>
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Subscribe now